$2.44
Today
as of Sep 4, 16:50 ET
Last 30 days
Recent Press Releases & News
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
INmune Bio (INMB) Q2 2026 Earnings Call Transcript
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ...
Overview
52-week range
$1.09
$2.50
96% of range
Avg surprise (last 2)
+4.1%
Avg reaction (last 2)
-3.3%
0% positive
Latest IV / EM
223%
EM ±34.8% · $2 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.05 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.20 | — | — | +53.5% | -5.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.24 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.34 | $-0.37 | +8.1% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.43 | $-0.43 | 0.0% | — | -0.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.60 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.50 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.61 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.48 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.36 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.36 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $50,000 | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-1M | $-6M | — | $-7M | $-25M | $-10M | — | $-12M |
| Net income | $-1M | $-5M | — | $-6M | $-24M | $-10M | — | $-12M |
| EPS (diluted) | $-0.05 | $-0.20 | — | $-0.24 | $-1.05 | $-0.43 | — | $-0.60 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | $28M | $33M | $19M | $21M | $34M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $24M | $23M | $30M | $31M | $36M | $21M | $23M | $36M |
| Total assets | $27M | $26M | $32M | $33M | $38M | $38M | $40M | $53M |
| Long-term debt | — | — | — | — | $15M | $15M | — | — |
| Total liabilities | $6M | $6M | $9M | $8M | $9M | $8M | $7M | $14M |
| Total equity | $20M | $20M | $24M | $25M | $29M | $30M | $32M | $39M |